These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

188 related articles for article (PubMed ID: 30298710)

  • 21. External validation of the Briganti nomogram to estimate the probability of specimen-confined disease in patients with high-risk prostate cancer.
    Roumiguié M; Beauval JB; Filleron T; Benoit T; Rischmann P; de la Taille A; Salomon L; Soulié M; Malavaud B; Ploussard G
    BJU Int; 2014 Dec; 114(6b):E113-E119. PubMed ID: 24684584
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pathologic Outcomes of Gleason 6 Favorable Intermediate-Risk Prostate Cancer Treated With Radical Prostatectomy: Implications for Active Surveillance.
    Yang DD; Mahal BA; Muralidhar V; Vastola ME; Boldbaatar N; Labe SA; Nezolosky MD; Orio PF; King MT; Martin NE; Mouw KW; Trinh QD; Nguyen PL
    Clin Genitourin Cancer; 2018 Jun; 16(3):226-234. PubMed ID: 29196209
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Prostate-specific antigen associates with extensive lymph node invasion in high-risk prostate cancer.
    Porcaro AB; Corsi P; Inverardi D; Sebben M; Tafuri A; Processali T; Mattevi D; De Marchi D; Pirozzi M; Cerruto MA; Amigoni N; Rizzetto R; Brunelli M; Siracusano S; Artibani W
    Tumori; 2018 Aug; 104(4):307-311. PubMed ID: 29714659
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Association of MyProstateScore (MPS) with prostate cancer grade in the radical prostatectomy specimen.
    Eyrich NW; Wei JT; Niknafs YS; Siddiqui J; Ellimoottil C; Salami SS; Palapattu GS; Mehra R; Kunju LP; Tomlins SA; Chinnaiyan AM; Morgan TM; Tosoian JJ
    Urol Oncol; 2022 Jan; 40(1):4.e1-4.e7. PubMed ID: 34753659
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Factors Predicting Tumour Upgrading in Patients Under Active Surveillance and Elected to Active Treatment after Disease Reclassification or Progression.
    Porcaro AB; Cavicchioli F; De Luyk N; Mattevi D; Corsi P; Sebben M; Tafuri A; Processali T; Inverardi D; Cacciamani G; De Marchi D; Balzarro M; Cerruto MA; Brunelli M; Novella G; Siracusano S; Artibani W
    Urol Int; 2017; 99(2):186-193. PubMed ID: 28196367
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Incidence of upgrading and upstaging in patients with low-volume Gleason score 3+4 prostate cancers at biopsy: finding a new group eligible for active surveillance.
    Park HJ; Ha YS; Park SY; Kim YT; Lee TY; Kim JH; Lee DH; Kim WJ; Kim IY
    Urol Int; 2013; 90(3):301-5. PubMed ID: 23391718
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Analysis of risk factors for Gleason score upgrading after radical prostatectomy in a Chinese cohort.
    Zhang B; Wu S; Zhang Y; Guo M; Liu R
    Cancer Med; 2021 Nov; 10(21):7772-7780. PubMed ID: 34528767
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Wisteria floribunda Agglutinin and Its Reactive-Glycan-Carrying Prostate-Specific Antigen as a Novel Diagnostic and Prognostic Marker of Prostate Cancer.
    Hagiwara K; Tobisawa Y; Kaya T; Kaneko T; Hatakeyama S; Mori K; Hashimoto Y; Koie T; Suda Y; Ohyama C; Yoneyama T
    Int J Mol Sci; 2017 Jan; 18(2):. PubMed ID: 28134773
    [No Abstract]   [Full Text] [Related]  

  • 29. LacdiNAc-Glycosylated Prostate-specific Antigen Density is a Potential Biomarker of Prostate Cancer.
    Inoue T; Kaneko T; Muramatsu S; Kimura H; Yoshino T; Goto T; Sawada A; Akamatsu S; Kobayashi T; Yamasaki T; Kaya T; Ogawa O
    Clin Genitourin Cancer; 2020 Feb; 18(1):e28-e36. PubMed ID: 31711843
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Percent of prostate needle biopsy cores with cancer is significant independent predictor of prostate specific antigen recurrence following radical prostatectomy: results from SEARCH database.
    Freedland SJ; Aronson WJ; Terris MK; Kane CJ; Amling CL; Dorey F; Presti JC;
    J Urol; 2003 Jun; 169(6):2136-41. PubMed ID: 12771735
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Performance characteristics of prostate-specific antigen density and biopsy core details to predict oncological outcome in patients with intermediate to high-risk prostate cancer underwent robot-assisted radical prostatectomy.
    Yashi M; Nukui A; Tokura Y; Takei K; Suzuki I; Sakamoto K; Yuki H; Kambara T; Betsunoh H; Abe H; Fukabori Y; Nakazato Y; Kaji Y; Kamai T
    BMC Urol; 2017 Jun; 17(1):47. PubMed ID: 28645325
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Risk of Pathologic Upgrading or Locally Advanced Disease in Early Prostate Cancer Patients Based on Biopsy Gleason Score and PSA: A Population-Based Study of Modern Patients.
    Caster JM; Falchook AD; Hendrix LH; Chen RC
    Int J Radiat Oncol Biol Phys; 2015 Jun; 92(2):244-51. PubMed ID: 25841621
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Low serum testosterone predicts upgrading and upstaging of prostate cancer after radical prostatectomy.
    Gao Y; Jiang CY; Mao SK; Cui D; Hao KY; Zhao W; Jiang Q; Ruan Y; Xia SJ; Han BM
    Asian J Androl; 2016; 18(4):639-43. PubMed ID: 26732103
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Non-organ confined stage and upgrading rates in exclusive PSA high-risk prostate cancer patients.
    Hoeh B; Flammia RS; Hohenhorst L; Sorce G; Chierigo F; Tian Z; Saad F; Gallucci M; Briganti A; Terrone C; Shariat SF; Graefen M; Tilki D; Kluth LA; Mandel P; Becker A; Chun FKH; Karakiewicz PI
    Prostate; 2022 May; 82(6):687-694. PubMed ID: 35188982
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Optimizing patient selection for prostate monotherapy.
    Lee AK; Schultz D; Renshaw AA; Richie JP; D'Amico AV
    Int J Radiat Oncol Biol Phys; 2001 Mar; 49(3):673-7. PubMed ID: 11172948
    [TBL] [Abstract][Full Text] [Related]  

  • 36. The clinical predictive factors and postoperative histopathological parameters associated with upgrading after radical prostatectomy: A contemporary analysis with grade groups.
    Erdem S; Verep S; Bagbudar S; Ozluk Y; Sanli O; Ozcan F
    Prostate; 2020 Feb; 80(2):225-234. PubMed ID: 31794085
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Role of PI-RADS Version 2 for Prediction of Upgrading in Biopsy-Proven Prostate Cancer With Gleason Score 6.
    Song W; Bang SH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Choi HY; Kim CK; Lee HM
    Clin Genitourin Cancer; 2018 Aug; 16(4):281-287. PubMed ID: 29550198
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Clinical Factors Predicting Bilateral Lymph Node Invasion in High-Risk Prostate Cancer.
    Porcaro AB; De Luyk N; Corsi P; Sebben M; Tafuri A; Processali T; Mattevi D; Pirozzi M; Cerruto MA; Amigoni N; Rizzetto R; Brunelli MA; Migliorini F; Siracusano S; Artibani W
    Urol Int; 2017; 99(4):392-399. PubMed ID: 28486228
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Predictors of Gleason Score (GS) upgrading on subsequent prostatectomy: a single Institution study in a cohort of patients with GS 6.
    Mehta V; Rycyna K; Baesens BM; Barkan GA; Paner GP; Flanigan RC; Wojcik EM; Venkataraman G
    Int J Clin Exp Pathol; 2012; 5(6):496-502. PubMed ID: 22949931
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Comparison of percentage of total prostate needle biopsy tissue with cancer to percentage of cores with cancer for predicting PSA recurrence after radical prostatectomy: results from the SEARCH database.
    Freedland SJ; Aronson WJ; Csathy GS; Kane CJ; Amling CL; Presti JC; Dorey F; Terris MK;
    Urology; 2003 Apr; 61(4):742-7. PubMed ID: 12670558
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.